Navigation Links
Abbott’s Laboratories R&D Capabilities Questione

Abbott Laboratories shares fell by 1.3% to close at $43.80 following U.S. Food and Drug Administration (FDA) rejection of its new drug Xinlay. Increased number of scientists and analysts question the efficiency of Abbott’s R&D // , after the rejection of its drug.

The drug that is to be used for the treatment of Prostate cancer failed in its Phase III trial leading to disapproval of the drug by the FDA Panel. Though Abbott is confident of its R&D capabilities and is sure of its other products like Humira, which is used in the treatment of Rheumatoid arthritis and its new drug eluting stent to be approved by the FDA, critics point out that Abbott is not winning in its R&D division as it is doing in Marketing. As FDA as put stringent and tough rules against approval of new drugs following the awful effects of the painkiller drug, Vioxx produced by Merck.

Mike Barr of Victory Capital Management said that, "What's a little disturbing is that Abbott's R&D productivity hasn't been all that great the last few years and looking at the history, they do a very good job at marketing, and it doesn't seem like R&D is up to the same caliber as their marketing." Victory Capital Management owns the shares of Abbott. Another Shareholder of Abbott is The Fifth Third Asset Management, this company is also not happy with Abbott and Mr. Jon Fisher of the company reported that, “It's evident as far as the absolute growth and profitability out of that business and I don't judge by the number of failures, but by the number of successes and how successful they are compared to their pharma peers. They're definitely on the lower end.

Glenn Novarro analyst in Banc of America Securities is optimistic about R&D of Abbott and said that though Xinlay may be a failure its other products in the pipeline like drugs Humira, Simdax, Febuxostat, drug eluting stent and Glucose monitor may succeed. "What is disappointing is that Abbott took a very aggressive approach with t his drug," by filing without a successful Phase III trial, Novarro said. "They clearly made a poor decision." He added, however, that in Abbott's defense, the company isn't a cancer specialist. "They're trying to break into the field, so it's not surprising there would be a stumble along the way."


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
2. Dr Reddy’s Laboratories launches Hyalosy
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
5. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
6. ICMR to Set up Laboratories to Combat Bird Flu
7. Ranbaxy Laboratories to Be Aided in Drug Research
8. Bangladesh to Set Up HIV/AIDS Diagnosis Laboratories
9. Drug Addicts To Prove ‘Child-Caring Capabilities’ By Clearing Drug Tess
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2017)... (PRWEB) , ... May 28, 2017 , ... HYPERAMS, ... a medical scrubs and uniform distributor based in Lima, Ohio. The sale began this ... approximately one million units of medical garments, scrubs, uniforms, and medical accessories, including blood ...
(Date:5/27/2017)... ... 27, 2017 , ... Hate visiting the dentist? You should go twice per year for checkups, ... your teeth at home. Here are some dental tips to help out: , 1. Brushing ... in your work desk or a locker at school for a quick brushing after lunch. ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American Parkinson Disease Association’s ... eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will be ... The American Parkinson Disease Association (APDA) is focused on advancing scientific research that ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... Agreements being discussed by President Donald Trump and the rest of the world. Donald ... up peace talks in the continuous battle between Israel and Palestine. The world’s eyes ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... May 15, 2017  Amy Baxter MD, chief executive ... in noninvasive pain relief, was awarded a 2017 Top ... Baxter was recognized at the MM&M Top 40 Healthcare ... City on May 10, 2017. The dinner ... industry go "beyond the pill."  "Innovation goes ...
(Date:5/12/2017)... TORONTO , May 12, 2017  The China and ... low-pressure washing technology that consumes less water, energy and detergent, and ... their first product LaughingU, a shoebox-sized washing machine that washes and ... ... First Product, LaughingU, is compact, and does not require an external ...
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
Breaking Medicine Technology: